Invivyd
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Invivyd sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Invivyd: 4 sponsored US clinical trials, 1 recruiting.
Invivyd sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 3 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is COVID-19, with 1 trials.
Upper-quartile sponsor footprint
Invivyd sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
NCT07655180
Study of VYD2311 for the Prevention of COVID-19
NCT07298434
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
NCT06039449
Evaluation of ADG20 for the Prevention of COVID-19
NCT04859517
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
Therapeutic Areas
Where Invivyd enrollment is open (later-stage tilt)
1 recruiting of 4 indexed (25% open); 1 completed (25%).
Phase mix: 3 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: COVID-19 (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Invivyd: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Invivyd sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Invivyd page
4 registered trials is a research-attention snapshot, not an endorsement of Invivyd or any single study.
- 1 of Invivyd's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- COVID-19 is the condition Invivyd studies most, compare against other sponsors active in the same condition before evaluating a specific study. See COVID-19 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Invivyd pipeline card: 4 registered trials from official public datasets.Report a data error.